Shopping Cart
- Remove All
- Your shopping cart is currently empty
WDR5-0102 is a compound that inhibits the WDR5-MLL1 interface (K dis = 7 μM, K d = 4 μM), selectively reducing MLL1 HMT activity without affecting the human H3K4 methyltransferase SETD7 or other HMTs, including G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $70 | In Stock | |
5 mg | $172 | In Stock | |
10 mg | $289 | In Stock | |
25 mg | $578 | In Stock | |
50 mg | $833 | In Stock | |
100 mg | $1,150 | In Stock | |
500 mg | $2,290 | In Stock | |
1 mL x 10 mM (in DMSO) | $226 | In Stock |
Description | WDR5-0102 is a compound that inhibits the WDR5-MLL1 interface (K dis = 7 μM, K d = 4 μM), selectively reducing MLL1 HMT activity without affecting the human H3K4 methyltransferase SETD7 or other HMTs, including G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5. |
Targets&IC50 | SHP2 (human):1.8 µM, WDR5-MLL1:7 μM(Kdis), WDR5-MLL1:4 μM(Kd) |
In vitro | Bioassay-guided fractionation resulted in the isolation of Mauritianin as a new topoisomerase I inhibitor.[1] After 14 weeks, Mauritianin antagonized the flavonol glycosides on cell-mediated immunosuppression in the two-stage carcinogenesis in terms of initiation.[3] |
Molecular Weight | 374.82 |
Formula | C18H19ClN4O3 |
Cas No. | 824960-50-1 |
Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 55 mg/mL (146.74 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.